{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:41:04Z","timestamp":1740123664329,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70110960"],"award-info":[{"award-number":["70110960"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Uveal melanoma (UM) is a rare tumor originating from melanocytic cells in the eye. Familial aggregation of UM is rare and can occur as part of the tumor predisposition syndrome BAP1-TPDS. However, family history alone will only identify a subset of patients with BAP1-TPDS. In the present study, we used sequential testing of tumor and blood DNA from UM patients for differential diagnosis of BAP1-TPDS. The study group was an unselected prospective cohort of patients from whom UM tissue was available. First, chromosome 3 status in tumor DNA was determined in all 140 patients who consented to participate. As tumors with disomy 3 rarely show BAP1 alterations, sequence analysis of this gene was performed in the 72 tumors with monosomy 3 (M3) or partial M3 only. We identified oncogenic BAP1 alterations in 52 of these tumors (72%). Targeted sequencing of DNA from matched peripheral blood showed pathogenic variants in two patients (3.8%) thus proving BAP1-TPDS. Only one of these two patients also had a medical history suggestive of this syndrome. Conversely, in three patients known to have had additional tumors before diagnosis of UM, constitutional heterozygosity for a <jats:italic>BAP<\/jats:italic>1 mutation was excluded. Altogether, in 50 patients we could exclude BAP1-TPDS with high diagnostic certainty. The results of our study support that genetic testing for BAP1-TPDS should be offered to all patients with UM. Moreover, as genetic information from the tumor can help exclude heritable risk, the strategy for analysis should include efforts to obtain tumor samples for testing.<\/jats:p>","DOI":"10.1007\/s10689-022-00310-3","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T10:03:01Z","timestamp":1659520981000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome"],"prefix":"10.1007","volume":"22","author":[{"given":"Yasaman Arjmand","family":"Abbassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Le Guin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Bornfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos E.","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zeschnigk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-9889","authenticated-orcid":false,"given":"Dietmar R.","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"2","key":"310_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL (2017) Uveal melanoma: relatively rare but deadly cancer. Eye (Lond) 31(2):241\u2013257. https:\/\/doi.org\/10.1038\/eye.2016.275","journal-title":"Eye (Lond)"},{"key":"310_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD (2017) Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 11:279\u2013289. https:\/\/doi.org\/10.2147\/OPTH.S89591","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"310_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/archopht.124.1.54","volume":"124","author":"E Weis","year":"2006","unstructured":"Weis E, Shah CP, Lajous M, Shields JA, Shields CL (2006) The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol 124(1):54\u201360. https:\/\/doi.org\/10.1001\/archopht.124.1.54","journal-title":"Arch Ophthalmol"},{"key":"310_CR4","doi-asserted-by":"publisher","first-page":"31191","DOI":"10.1038\/srep31191","volume":"6","author":"R Ferguson","year":"2016","unstructured":"Ferguson R, Vogelsang M, Ucisik-Akkaya E et al (2016) Genetic markers of pigmentation are novel risk loci for uveal melanoma. Sci Rep 6:31191. https:\/\/doi.org\/10.1038\/srep31191","journal-title":"Sci Rep"},{"issue":"1","key":"310_CR5","first-page":"17","volume":"99","author":"HT Lynch","year":"1968","unstructured":"Lynch HT, Krush AJ (1968) Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J 99(1):17\u201321","journal-title":"Can Med Assoc J"},{"issue":"4","key":"310_CR6","first-page":"308","volume":"32","author":"F Vogel","year":"1954","unstructured":"Vogel F (1954) Genetics and mutation rate of retinoblastoma (glioma retinae), with general remarks on methods of determining mutation rate in humans. Z Mensch Vererb Konstitutionsl 32(4):308\u2013336","journal-title":"Z Mensch Vererb Konstitutionsl"},{"issue":"4","key":"310_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr","year":"1971","unstructured":"Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68(4):820\u2013823. https:\/\/doi.org\/10.1073\/pnas.68.4.820","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"310_CR8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","volume":"43","author":"T Wiesner","year":"2011","unstructured":"Wiesner T, Obenauf AC, Murali R et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018\u20131021. https:\/\/doi.org\/10.1038\/ng.910","journal-title":"Nat Genet"},{"issue":"12","key":"310_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","volume":"48","author":"MH Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman MH, Pilarski R, Cebulla CM et al (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856\u2013859. https:\/\/doi.org\/10.1136\/jmedgenet-2011-100156","journal-title":"J Med Genet"},{"issue":"11","key":"310_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/0008-5472.CAN-20-3430","volume":"81","author":"A Han","year":"2021","unstructured":"Han A, Purwin TJ, Aplin AE (2021) Roles of the BAP1 tumor suppressor in cell metabolism. Cancer Res 81(11):2807\u20132814. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3430","journal-title":"Cancer Res"},{"issue":"8","key":"310_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone M, Harbour JW, Brugarolas J et al (2020) Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov 10(8):1103\u20131120. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1220","journal-title":"Cancer Discov"},{"key":"310_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ferris LK, Baumann F et al (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10:179. https:\/\/doi.org\/10.1186\/1479-5876-10-179","journal-title":"J Transl Med"},{"issue":"10","key":"310_CR13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022\u20131025. https:\/\/doi.org\/10.1038\/ng.912","journal-title":"Nat Genet"},{"issue":"12","key":"310_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","volume":"110","author":"S Walpole","year":"2018","unstructured":"Walpole S, Pritchard AL, Cebulla CM et al (2018) Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst 110(12):1328\u20131341. https:\/\/doi.org\/10.1093\/jnci\/djy171","journal-title":"J Natl Cancer Inst"},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.12.022","volume":"92","author":"P Star","year":"2018","unstructured":"Star P, Goodwin A, Kapoor R et al (2018) Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer 92:48\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.022","journal-title":"Eur J Cancer"},{"issue":"2","key":"310_CR16","first-page":"301","volume":"59","author":"HZ Noorani","year":"1996","unstructured":"Noorani HZ, Khan HN, Gallie BL, Detsky AS (1996) Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 59(2):301\u2013307","journal-title":"Am J Hum Genet"},{"issue":"2","key":"310_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1086\/514845","volume":"61","author":"DR Lohmann","year":"1997","unstructured":"Lohmann DR, Gerick M, Brandt B et al (1997) Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet 61(2):282\u2013294. https:\/\/doi.org\/10.1086\/514845","journal-title":"Am J Hum Genet"},{"issue":"10","key":"310_CR18","first-page":"2578","volume":"63","author":"F Tschentscher","year":"2003","unstructured":"Tschentscher F, Husing J, Holter T et al (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63(10):2578\u20132584","journal-title":"Cancer Res"},{"issue":"1","key":"310_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0165-4608(00)00266-1","volume":"122","author":"F Tschentscher","year":"2000","unstructured":"Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR (2000) Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 122(1):13\u201317. https:\/\/doi.org\/10.1016\/s0165-4608(00)00266-1","journal-title":"Cancer Genet Cytogenet"},{"issue":"8","key":"310_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Masshofer L, Temming P et al (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45(8):933\u2013936. https:\/\/doi.org\/10.1038\/ng.2674","journal-title":"Nat Genet"},{"issue":"5","key":"310_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"1","key":"310_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s12885-018-5079-x","volume":"18","author":"KG Ewens","year":"2018","unstructured":"Ewens KG, Lalonde E, Richards-Yutz J, Shields CL, Ganguly A (2018) Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma. BMC Cancer 18(1):1172. https:\/\/doi.org\/10.1186\/s12885-018-5079-x","journal-title":"BMC Cancer"},{"issue":"1","key":"310_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","volume":"9","author":"MG Field","year":"2018","unstructured":"Field MG, Durante MA, Anbunathan H et al (2018) Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun 9(1):116. https:\/\/doi.org\/10.1038\/s41467-017-02428-w","journal-title":"Nat Commun"},{"issue":"1","key":"310_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/gcc.22218","volume":"54","author":"M Betti","year":"2015","unstructured":"Betti M, Casalone E, Ferrante D et al (2015) Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 54(1):51\u201362. https:\/\/doi.org\/10.1002\/gcc.22218","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"310_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","volume":"17","author":"M Carbone","year":"2022","unstructured":"Carbone M, Pass HI, Ak G et al (2022) Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations. J Thorac Oncol 17(7):873\u2013889. https:\/\/doi.org\/10.1016\/j.jtho.2022.03.014","journal-title":"J Thorac Oncol"},{"issue":"10","key":"310_CR26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/ng.3664","volume":"48","author":"RG Lindeboom","year":"2016","unstructured":"Lindeboom RG, Supek F, Lehner B (2016) The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet 48(10):1112\u20131118. https:\/\/doi.org\/10.1038\/ng.3664","journal-title":"Nat Genet"},{"issue":"3","key":"310_CR27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1074\/jbc.M114.609834","volume":"290","author":"Y Okino","year":"2015","unstructured":"Okino Y, Machida Y, Frankland-Searby S, Machida YJ (2015) BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes. J Biol Chem 290(3):1580\u20131591. https:\/\/doi.org\/10.1074\/jbc.M114.609834","journal-title":"J Biol Chem"},{"issue":"6","key":"310_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/PAS.0000000000000645","volume":"40","author":"JA van de Nes","year":"2016","unstructured":"van de Nes JA, Nelles J, Kreis S et al (2016) Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma. Am J Surg Pathol 40(6):796\u2013805. https:\/\/doi.org\/10.1097\/PAS.0000000000000645","journal-title":"Am J Surg Pathol"},{"key":"310_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41525-020-00157-6","volume":"5","author":"JH Hong","year":"2020","unstructured":"Hong JH, Chong ST, Lee PH et al (2020) Functional characterisation guides classification of novel BAP1 germline variants. NPJ Genom Med 5:50. https:\/\/doi.org\/10.1038\/s41525-020-00157-6","journal-title":"NPJ Genom Med"},{"issue":"14","key":"310_CR30","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/hmg\/ddz076","volume":"28","author":"P Repo","year":"2019","unstructured":"Repo P, Jarvinen RS, Jantti JE et al (2019) Population-based analysis of BAP1 germline variations in patients with uveal melanoma. Hum Mol Genet 28(14):2415\u20132426. https:\/\/doi.org\/10.1093\/hmg\/ddz076","journal-title":"Hum Mol Genet"},{"key":"310_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081114","author":"C Chau","year":"2019","unstructured":"Chau C, van Doorn R, van Poppelen NM et al (2019) Families with BAP1-tumor predisposition syndrome in The Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11081114","journal-title":"Cancers (Basel)"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-022-00310-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T09:19:42Z","timestamp":1678958382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-022-00310-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s10689-022-00310-3","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"type":"print","value":"1389-9600"},{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University Hospital Essen (13\u20135462-B0).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate was given by every patient included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients included in this study signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}